Affluent Partners Holdings (1466) AI Stock Analysis

• Market Cap: HK$512.74M
• Dividend Yield: N/A
• Average Volume (3M): 304.34K
• Price to Earnings (P/E): 49.8
• Beta (1Y): 0.19
• Revenue Growth: 20.46%
• EPS Growth: N/A
• Country: HK
• Employees: 84
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Luxury Goods
• EPS (TTM): <0.01
• Shares Outstanding: 932,254,100
• 10 Day Avg. Volume: 457,992
• 30 Day Avg. Volume: 304,341
• PEG Ratio: 0.30
• Price to Book (P/B): 4.22
• Price to Sales (P/S): 7.57
• P/FCF Ratio: -61.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: HK$0.53 ▼(-2.78% Downside)
• Action: Reiterated Date: 01/15/26
• Date: Action: Reiterated 01/15/26

The score is constrained primarily by weak profitability and negative operating/free cash flows despite strong revenue growth. Technical indicators are moderately supportive (price above major short- and mid-term averages with positive MACD), but valuation is a headwind with a high P/E and no dividend yield provided.

Positive Factors

Revenue Growth

Reported 36.3% revenue growth shows durable top-line expansion and continued customer demand. Sustained high revenue growth underpins scale advantages, supports pricing leverage and market-share gains if margins and cash conversion improve over the medium term.

Manageable Leverage

A debt-to-equity of 0.72 with a stable equity base indicates financial flexibility to fund operations or strategic investments without excessive leverage. Manageable indebtedness lowers refinancing risk and supports multi-quarter execution of growth initiatives.

Improving FCF Growth

Positive free cash flow growth, despite current negatives, signals improving cash conversion trends. If sustained, this trend can lead to durable self-funding of capex and working capital and reduce reliance on external financing over several quarters.

Negative Factors

Weak Profitability

Negative net profit and EBIT margins show the company cannot yet convert strong sales into operating profits. Persistent margin deficits strain reinvestment capacity and make long-term returns dependent on significant cost improvements or higher gross margins.

Negative Cash Generation

Reported negative operating and free cash flows point to ongoing cash burn and potential liquidity pressure. Over a multi-month horizon this can force dilutive financing, capex cuts or slowed expansion unless cash conversion and working capital are materially improved.

Poor Return on Equity

Negative ROE despite a healthy equity base means capital is not generating returns. This structural weakness undermines long-term shareholder value creation and limits ability to self-fund growth unless profitability and asset efficiency are restored.

Affluent Partners Holdings Business Overview & Revenue Model

Company Description

Affluent Partners Holdings Limited, an investment holding company, engages in the purchase, process, design, production, assembly, trade, and wholesale distribution of pearls and jewelry products. It operates in two segments, Sales of Pearls and Jewellery Products, and Strategic Investment and Financial Services. The company is also involved in the real estate financial assets investment business. It has operations in Hong Kong, the United Kingdom, the United States, Japan, Europe, and the People's Republic of China. The company was formerly known as Man Sang Jewellery Holdings Limited and changed its name to Affluent Partners Holdings Limited in February 2017. Affluent Partners Holdings Limited was incorporated in 2014 and is based in Central, Hong Kong.

How the Company Makes Money

Affluent Partners Holdings Financial Statement Overview

Summary

Strong revenue growth (36.3%) is offset by weak profitability (negative net profit and EBIT margins) and pressured cash generation (negative operating and free cash flows). Balance sheet leverage appears manageable (debt-to-equity 0.72), but negative ROE signals poor returns.

Income Statement

The company has shown significant revenue growth of 36.3% in the latest year, indicating strong sales performance. However, profitability remains a concern with a negative net profit margin and EBIT margin, reflecting ongoing operational challenges. The gross profit margin is moderate, suggesting some efficiency in cost management but not enough to offset other expenses.

Balance Sheet

The balance sheet shows a stable equity base with a debt-to-equity ratio of 0.72, which is manageable. However, the return on equity is negative, indicating that the company is not generating sufficient returns on its equity. The equity ratio is relatively healthy, suggesting a solid asset base.

Cash Flow

Cash flow analysis reveals a challenging situation with negative operating and free cash flows, indicating liquidity issues. The free cash flow growth is positive, but the overall cash flow position needs improvement to support operations and growth.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	119.80M	135.56M	86.88M	62.65M	43.32M	111.98M
Gross Profit	33.67M	41.99M	7.83M	10.99M	-8.62M	28.55M
EBITDA	10.47M	6.26M	11.13M	-9.73M	-45.45M	-268.12M
Net Income	8.08M	-316.00K	8.73M	-15.46M	-51.78M	-281.82M
Balance Sheet
Total Assets	281.67M	290.17M	99.85M	82.11M	91.77M	158.66M
Cash, Cash Equivalents and Short-Term Investments	57.46M	47.77M	41.26M	23.59M	24.42M	34.49M
Total Debt	85.43M	99.93M	2.76M	31.84M	31.56M	39.50M
Total Liabilities	123.85M	134.30M	21.51M	46.24M	45.82M	73.53M
Stockholders Equity	140.88M	139.28M	78.34M	35.87M	45.95M	85.13M
Cash Flow
Free Cash Flow	-15.37M	-32.97M	-21.55M	1.06M	-16.21M	-1.29M
Operating Cash Flow	-13.21M	-30.53M	-21.52M	1.11M	-16.18M	2.33M
Investing Cash Flow	-1.17M	-846.00K	35.30M	-60.00K	138.00K	39.15M
Financing Cash Flow	25.72M	41.41M	3.70M	-1.72M	6.77M	-35.22M

Affluent Partners Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1466, the sentiment is Positive. The current price of 0.54 is above the 20-day moving average (MA) of 0.53, below the 50-day MA of 0.54, and below the 200-day MA of 0.59, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.23 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1466.

Affluent Partners Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0280	73 Outperform	HK$472.84M	2.83	11.02%	6.00%	14.52%	15.74%
0398	70 Outperform	HK$1.64B	4.06	10.00%	9.67%	-9.00%	-21.55%
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
1466	52 Neutral	HK$512.74M	49.76	7.10%	―	20.46%	―
0789	51 Neutral	HK$476.63M	-91.13	2.72%	―	60.75%	-63.30%
3389	50 Neutral	HK$827.96M	4.39	-1.15%	―	-41.44%	-209.76%
1856	45 Neutral	HK$666.48M	-3.93	-65.71%	―	-20.65%	-616.18%

Affluent Partners Holdings Corporate Events

Baijin Life Science Adds Independent Director to Restore Governance Compliance

Baijin Life Science Holdings has appointed Ms. Shen Ding as an independent non‑executive director and member of its audit, remuneration and nomination committees, effective 2 March 2026. Shen brings experience in equity investment, asset management and securities regulation, having previously held senior roles at Mingya Fund Management, Beijing Xiangyi Asset Management and the China Securities Regulatory Commission.

With Shen’s appointment, the board now includes three independent non‑executive directors, enabling Baijin Life Science to restore full compliance with Hong Kong listing rules governing board independence and key governance committees. Her addition is expected to strengthen the company’s corporate governance framework and reassure investors about its adherence to regulatory standards and oversight requirements.

The most recent analyst rating on (HK:1466) stock is a Sell with a HK$0.49 price target. To see the full list of analyst forecasts on Affluent Partners Holdings stock, see the HK:1466 Stock Forecast page.

Baijin Life Science Clarifies Board and Committee Roles in Governance Update

Baijin Life Science Holdings has released an updated list of its directors and clarified the composition of its three key board committees. The announcement confirms the roles of executive, non-executive and independent non-executive directors, with Wong Siu Keung, Joe serving as chairman of the audit, remuneration and nomination committees, reinforcing the company’s corporate governance framework.

The detailed allocation of committee memberships, including independent directors as members across all three committees, underscores a focus on oversight of financial reporting, pay policies and board nominations. This structure is likely intended to align the company with prevailing governance standards for Hong Kong-listed issuers and provide greater transparency to investors about decision-making responsibilities at board level.

The most recent analyst rating on (HK:1466) stock is a Sell with a HK$0.49 price target. To see the full list of analyst forecasts on Affluent Partners Holdings stock, see the HK:1466 Stock Forecast page.

Baijin Life Science Director Resigns, Triggering Temporary Governance Non-Compliance

Baijin Life Science Holdings has announced the resignation of independent non-executive director (INED) Mr. Lee Ka Leung Daniel, who has also stepped down as chairman of the audit committee and as a member of the remuneration and nomination committees, effective 27 January 2026, citing personal reasons and confirming no disagreement with the board. His departure leaves the company temporarily in breach of several Hong Kong Listing Rules regarding the required number and proportion of INEDs and the composition of the audit, remuneration and nomination committees, prompting Baijin to initiate a search for a replacement INED and new committee members while appointing existing INED Mr. Wong Siu Keung Joe as the new chairman of the audit committee, a move that underscores both a near-term governance gap and the board’s efforts to restore full regulatory compliance.

The most recent analyst rating on (HK:1466) stock is a Sell with a HK$0.58 price target. To see the full list of analyst forecasts on Affluent Partners Holdings stock, see the HK:1466 Stock Forecast page.

Baijin Life Science Sets Out Board and Committee Structure

Baijin Life Science Holdings Limited has announced the composition of its board of directors, comprising executive, non-executive and independent non-executive directors, as well as the structure of its three key board committees. The company has confirmed the membership and leadership roles for the Audit, Remuneration and Nomination Committees, with independent non-executive director Wong Siu Keung, Joe serving as chairman of all three, underscoring the firm’s focus on board independence and corporate governance oversight, which is likely to be closely watched by shareholders and regulators alike.

The most recent analyst rating on (HK:1466) stock is a Sell with a HK$0.58 price target. To see the full list of analyst forecasts on Affluent Partners Holdings stock, see the HK:1466 Stock Forecast page.